Syncona CEO On Why Its 10th Start-Up Focuses On T-Regulatory Cell Therapies

 
• By Sten Stovall

UK investment group Syncona Ltd has financed its tenth start-up, Quell Therapeutics, with the aim of developing engineered T regulatory (Treg) cell therapies.

T cells
Syncona founded Quell Therapeutics with £35m Series A Financing • Source: Shutterstock

More from Business

More from Scrip